News

The portfolio, in addition to 25 new raw materials, comprises 65 high-quality buffers, amino acids and specialty chemicals. The PharmaGrade products are documented with the production history that

Net sales for the third quarter of 2012 were $18.13m compared to $17.06m last year. The company reported a net loss of $10,911, or $0 per share, for

The drugs resulting from the partnership are expected to target a human protein that is vital for the spread of pathogenic viral infection in the host cell. Haplogen

Data demonstrated that Complera is non-inferior to Atripla, achieving HIV RNA levels less than 50 copies/mL through 48 weeks of therapy, the primary endpoint of the study. On

Impax Laboratories and its subsidiary ThoRx Laboratories have been challenged by US-based Endo Pharmaceuticals and German’s Grunenthal on 14 November 2012, regarding the patents of Opana® ER tablets,

With the move the company plans to increase its foothold in the US with the help of existing European and US pharmaceutical regulations. SDI America president Danny Cusick

According to the company the increased loss is due to the $155,000 increase in general and administration expenses, a $33,000 increase in business development expenses and a $28,000

The new facility for Shanghai Promega Biological Products will replace present molecular biology reagent production site and also provide additional research, development and cGMP manufacturing capabilities for molecular

As part of Series B financing, the firm has already raised about $25m from pharmaceutical major Eli Lilly and global financial services firm Fidelity. With plans underway to